Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
-1.84 (-0.49%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 369.30 - 375.00
52 week 325.35 - 452.96
Open 372.42
Vol / Avg. 0.00/1.06M
Mkt cap 39.18B
P/E 48.14
Div/yield     -
EPS 7.71
Shares 104.17M
Beta 1.44
Inst. own 70%
Feb 7, 2017
Q4 2016 Regeneron Pharmaceuticals Inc Earnings Release (Estimated)
Jan 9, 2017
Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A
Jan 9, 2017
Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 20.63% 18.42%
Operating margin 28.28% 27.38%
EBITD margin - 29.53%
Return on average assets 14.71% 14.23%
Return on average equity 22.71% 22.10%
Employees 5,400 -
CDP Score - 59 E


777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 86
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
Daniel P. Van Plew Executive Vice President, General Manager - Industrial Operations and Product Supply
Age: 43
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Executive Vice President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Robert J. Terifay Executive Vice President - Commercial
Age: 56
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Michael Aberman M.D. Senior Vice President - Strategy and Investor Relation
Age: 45
Bio & Compensation  - Reuters
Jay S. Markowitz M.D. Senior Vice President - Portfolio Management
Bio & Compensation  - Reuters
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 59
Bio & Compensation  - Reuters